Paul Nghiem, MD, PhD - Division Chair
Professor
Division of Dermatology
Adjunct Professor
Department of Pathology
Adjunct Professor
Department of Oral Health Sciences
Head of the Division of Dermatology
George F. Odland Endowed Chair in Dermatology
Dermatology Site Director, Seattle Cancer Care Alliance

Faculty Information

Biography

Paul Nghiem, M.D., Ph.D., is a board certified physician at SCCA, head of UW Dermatology, the George F. Odland Endowed Chair in Dermatology and a UW professor of Medicine and Dermatology and an adjunct professor in the Departments of Laboratory Medicine and Pathology as well as Oral Health Sciences. Dr. Nghiem oversees the Nghiem Lab, a laboratory focused on the biology of skin cancer. Dr. Nghiem earned his M.D. and Ph.D. at Stanford. His clinical and research interests include dermatology, Merkel cell carcinoma, melanoma, graft versus host disease and complex skin cancer management in a multidisciplinary team.

Dr. Nghiem holds the following leadership roles in the Dermatology and Skin Oncology community:

  • Director, Skin Oncology Clinical Program, Seattle Cancer Care Alliance
  • Deputy Director for Seattle Translational Tumor Research, Skin/Cutaneous Oncology
  • Secretary-Treasurer, Society for Investigative Dermatology
Education & Training: 
MD
Stanford University School of Medicine
Stanford CA
1994
PhD
Stanford University, Program in Cancer Biology
Stanford CA
1994
A.B.
Biological Sciences, Harvard University
Boston MA
1986
Contact
Mailing Address: 

Research Office:

UW Medical Center
at South Lake Union
850 Republican Street
Box 358050
Seattle, WA 98195-8050

New Patient scheduling:
206-288-1024

Established Patient matters:
206-288-1160

Patient care-related matters:
Seattle Cancer Care Alliance
825 Eastlake Avenue East
4th Floor
Box 358050
Seattle, WA 98195-8050

 

Research & Clinical Interests
Research Interests: 

A major portion of the Nghiem lab is primarily focused on basic, clinical and translational research aspects of Merkel cell carcinoma. We are involved in several clinical studies on this increasingly common and often lethal skin cancer to determine its basic genetic underpinnings as well as its clinical course and optimal management. The Merkel cell carcinoma Multicenter Interest Group (MMIG), is an international collaborative group, has been formed to leverage diverse resources, interests and expertise to make a difference in this cancer.

A second research interest is focused on skin cancer biology, particularly the molecular mechanism by which the protein kinase ATR mediates an essential cell cycle arrest following DNA damage such as by ultraviolet radiation.  It appears that the skin cancer preventive effect of caffeine is mediated by its inhibition on the ATR-Chk1 pathway, hence eliminating UV-damaged cells from the skin.

View Nghiem Lab Website

Clinical Interests: 

View Clinical Publications

Publications
Publications: 

Selected Publications

Dr. Nghiem has over 170 publications that have been cited 10,907 times as of August 5, 2019, with an h-index of 54 and an i10-index of 122 according to Google Scholar.

Heath, M; Jaimes, N; Lemos, B;  Mostaghimi, A; Wang, L C; Peñas, P F; Nghiem, P; Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. Journal of the American Academy of Dermatology. 58 (3): 375-381, 2008. Cited 793 times

Bianca D Lemos, Barry E Storer, Jayasri G Iyer, Jerri Linn Phillips, Christopher K Bichakjian, L Christine Fang, Timothy M Johnson, Nanette J Liegeois-Kwon, Clark C Otley, Kelly G Paulson, Merrick I Ross, Siegrid S Yu, Nathalie C Zeitouni, David R Byrd, Vernon K Sondak, Jeffrey E Gershenwald, Arthur J Sober, Paul Nghiem. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. Journal of the American Academy of Dermatology. 63(5): 751-761, 2010. Cited 506 times

Paulson, K G; Carter, J J; Johnson, L G; Cahill, K W; Iyer, J G; Schrama, D; Becker, J C; Madeleine, M M; Nghiem, P; Galloway, D A. Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Research. 70(21): 8388-8397. 2010. Cited 192 times

Afanasiev, O K; Yelistratova, L; Miller, N; Nagase, K; Paulson, K; Iyer, J G; Ibrani, D; Koelle, D M; Nghiem, P. Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clinical Cancer Research. 19(19): 5351-5360, 2013. Cited 149 times

Nghiem, P T; Bhatia, S; Lipson, E J; Kudchadkar, R R; Miller, N J; Annamalai, L; Berry, S; Chartash, E K; Daud, A; Fling, S P. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. New England Journal of Medicine. 374(26): 2542-2552, 2016. Cited 763 times

View Basic Research Publications